OATD-02 | arginase inhibitor | CAS#2146132-73-0

MedKoo Cat#: 128155 | Name: OATD-02

Description:

WARNING: This product is for research use only, not for human or veterinary use.

OATD-02 is an arginase inhibitor.

Chemical Structure

OATD-02

CAS#2146132-73-0

Theoretical Analysis

MedKoo Cat#: 128155

Name: OATD-02

CAS#: 2146132-73-0

Chemical Formula: C12H25BN2O4

Exact Mass: 272.1907

Molecular Weight: 272.15

Elemental Analysis: C, 52.96; H, 9.26; B, 3.97; N, 10.29; O, 23.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

OATD-02; OATD02; OATD 02

IUPAC/Chemical Name

(1R,2S,5R)-1-amino-5-(2-boronoethyl)-2-((dimethylamino)methyl)cyclohexane-1-carboxylic acid

InChi Key

NZNAXQBYXLSQHO-JBLDHEPKSA-N

InChi Code

InChI=1S/C12H25BN2O4/c1-15(2)8-10-4-3-9(5-6-13(18)19)7-12(10,14)11(16)17/h9-10,18-19H,3-8,14H2,1-2H3,(H,16,17)/t9-,10-,12+/m0/s1

SMILES Code

N[C@@]1(C[C@@H](CC[C@H]1CN(C)C)CCB(O)O)C(O)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 272.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Grzybowski MM, Stańczak PS, Pomper P, Błaszczyk R, Borek B, Gzik A, Nowicka J, Jędrzejczak K, Brzezińska J, Rejczak T, Güner-Chalimoniuk NC, Kikulska A, Mlącki M, Pęczkowicz-Szyszka J, Olczak J, Gołębiowski A, Dzwonek K, Dobrzański P, Zasłona Z. OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer. Cancers (Basel). 2022 Aug 17;14(16):3967. doi: 10.3390/cancers14163967. PMID: 36010962; PMCID: PMC9406419. 2: Borek B, Nowicka J, Gzik A, Dziegielewski M, Jedrzejczak K, Brzezinska J, Grzybowski M, Stanczak P, Pomper P, Zagozdzon A, Rejczak T, Matyszewski K, Golebiowski A, Olczak J, Lisiecki K, Tyszkiewicz M, Kania M, Piasecka S, Cabaj A, Dera P, Mulewski K, Chrzanowski J, Kusmirek D, Sobolewska E, Magdycz M, Mucha L, Masnyk M, Golab J, Nowotny M, Nowak E, Napiorkowska-Gromadzka A, Pikul S, Jazwiec R, Dzwonek K, Dobrzanski P, Meyring M, Skowronek K, Iwanowski P, Zaslona Z, Blaszczyk R. Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy. Mol Cancer Ther. 2023 Jul 5;22(7):807-817. doi: 10.1158/1535-7163.MCT-22-0721. PMID: 36939275. 3: Gzik A, Borek B, Chrzanowski J, Jedrzejczak K, Dziegielewski M, Brzezinska J, Nowicka J, Grzybowski MM, Rejczak T, Niedzialek D, Wieczorek G, Olczak J, Golebiowski A, Zaslona Z, Blaszczyk R. Novel orally bioavailable piperidine derivatives as extracellular arginase inhibitors developed by a ring expansion. Eur J Med Chem. 2024 Jan 15;264:116033. doi: 10.1016/j.ejmech.2023.116033. Epub 2023 Dec 10. PMID: 38096651.